Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced results of a study in which Azilect® (rasagiline tablets) demonstrated selective MAO – B inhibition at the approved dose of 1mg. Non selective MAO inhibitors may have some contra indications with certain foods and drugs. These limitations are not associated with selective MAO inhibitors and therefore they can be broadly prescribed. Based on these positive results, Teva will work with the U.S.
Popularity: unranked [?]
Related posts:
- News From The Canadian Medical Association Journal
- Depression And Osteoporosis Connection Shown By Hebrew University Researchers
- New Research Shows Returning To Work Can Aid People With Depression
- NY Health Department Launches MySpace Campaign To Help Young New Yorkers Cope
- HIV-Positive People With Depression More Likely To Follow Treatment Regimens When Taking SSRIs, Study Finds
Comments
No Responses to “AZILECT(R) Shown To Be A Selective MAO-B Inhibitor – Teva To Work With FDA To Modify The Azilect(R) Label”